UNITED STATES OF AMERICA

DEPARTMENT OF TRANSPORTATION

OFFICE OF THE SECRETARY

WASHINGTON, D.C.

Issued by the Department of Transportation on August 18, 2006

NOTICE OF ACTION TAKEN -- DOCKET OST-2004-17411

________________________________________________________________________
________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Applicant: AEROMODELO, S.A. de C.V.		  			Date Filed: May 25, 2005

Relief requested:  Renewal of exemption from 49 U.S.C. § 41301 to
permit the applicant to conduct passenger charter operations between
Mexico and the United States, and other passenger charters in accordance
with 14 CFR Part 212, using small equipment.

If renewal, date and citation of last action:  May 25, 2004, in this
Docket.

Applicant representative:  James E. Ramsey,<PHONE_NUMBER>	  DOT analyst:
Robert J. Finamore,<PHONE_NUMBER>

Responsive pleadings:  None.

	DISPOSITION

Action:  Approved.
                                          Action date:  August 18, 2006

Effective dates of authority granted:  August 18, 2006, through August
18, 2007.

Basis for approval (bilateral agreement/reciprocity): United
States-Mexico Air Transport Services Agreement (“the Agreement”).

Except to the extent exempted/waived, this authority is subject to the
terms, conditions, and limitations of our standard exemption conditions
(attached).

Special conditions/Remarks:  In the conduct of these operations, the
carrier may only use aircraft capable of carrying no more than 60
passengers and having a maximum payload capacity of no more than 18,000
pounds (small equipment).  The above grant includes authority to operate
Third and Fourth Freedom charters.  While we have subjected, consistent
with the provisions of the Agreement, Mexican carriers conducting
charter operations with large aircraft to prior approval or submission
of notice for their Third and Fourth Freedom charters, we determined
that any such requirement was not necessary on public interest grounds
in the case of this carrier, since the carrier will be conducting these
operations solely with small aircraft.  (Other charter operations
to/from the United States under this authority, however, are subject to
prior approval under 14 CFR Part 212.)  Further, we are continuing to
allow Mexican carriers conducting passenger charters using small
equipment to make stopovers in the United States in the conduct of such
operations.

Action taken by:   Paul L. Gretch, Director, Office of International
Aviation

________________________________________________________________________
_______________________

Under authority assigned by the Department in its regulations, 14 CFR
Part 385, we found that (1) our action was consistent with Department
policy; (2) the applicant was qualified to perform its proposed
operations; (3) grant of the authority was consistent with the public
interest; and (4) grant of the authority would not constitute a major
regulatory action under the Energy Policy and Conservation Act of 1975.
To the extent not granted/deferred/dismissed, we denied all requests in
the referenced Docket.  We may amend, modify, or revoke the authority
granted in this Notice at any time without hearing at our discretion.

Persons entitled to petition the Department for review of the action set
forth in this Notice under the Department’s regulations, 14 CFR
§385.30, may file their petitions within seven (7) days after the date
of issuance of this Notice.  This action was effective when taken, and
the filing of a petition for review will not alter such effectiveness.

An electronic version of this document is available on the World Wide
Web at:

http://dms.dot.gov//reports/reports_aviation.asp

FOREIGN CARRIER EXEMPTION CONDITIONS
                              ATTACHMENT

In the conduct of the operations authorized, the foreign carrier
applicant(s) shall:

1) Not conduct any operations unless it holds a currently effective
authorization from its homeland for such operations, and it has filed a
copy of such authorization with the Department;

2) Comply with all applicable requirements of the Federal Aviation
Administration, including, but not limited to, 14 CFR Parts 129, 91, and
36, and with all applicable U.S. Government requirements concerning
security, including, but not limited to, 49 CFR Part 1546 or 1550, as
applicable.  To assure compliance with all applicable U.S. Government
requirements concerning security, the holder shall, before commencing
any new service (including charter flights) from a foreign airport that
would be the holder’s last point of departure for the United States,
contact its International Principal Security Inspector (IPSI) to advise
the IPSI of its plans and to find out whether the Transportation
Security Administration has determined that security is adequate to
allow such airport(s) to be served;

3) Comply with the requirements for minimum insurance coverage contained
in 14 CFR Part 205, and, prior to the commencement of any operations
under this authority, file evidence of such coverage, in the form of a
completed OST Form 6411, with the Federal Aviation Administration’s
Program Management Branch (AFS-260), Flight Standards Service (any
changes to, or termination of, insurance also shall be filed with that
office);

4) Not operate aircraft under this authority unless it complies with
operational safety requirements at least equivalent to Annex 6 of the
Chicago Convention;

5) Conform to the airworthiness and airman competency requirements of
its Government for international air services;

6) Except as specifically exempted or otherwise provided for in a
Department Order, comply with the requirements of 14 CFR Part 203,
concerning waiver of Warsaw Convention liability limits and defenses;

7) Agree that operations under this authority constitute a waiver of
sovereign immunity, for the purposes of 28 U.S.C. 1605(a), but only with
respect to those actions or proceedings instituted against it in any
court or other tribunal in the United States that are: a) based on its
operations in international air transportation that, according to the
contract of carriage, include a point in the United States as a point of
origin, point of destination, or agreed stopping place, or for which the
contract of carriage was purchased in the United States; or b) based on
a claim under any international agreement or treaty cognizable in any
court or other tribunal of the United States.  In this condition, the
term “international air transportation” means “international
transportation” as defined by the Warsaw Convention, except that all
States shall be considered to be High Contracting Parties for the
purpose of this definition;

8) Except as specifically authorized by the Department, originate or
terminate all flights to/from the United States in its homeland;

9) Comply with the requirements of 14 CFR Part 217, concerning the
reporting of scheduled, nonscheduled, and charter data;

10) If charter operations are authorized, except as otherwise provided
in the applicable aviation agreement, comply with the Department’s
rules governing charters (including 14 CFR Parts 212 and 380); and

11) Comply with such other reasonable terms, conditions, and limitations
required by the public interest as may be prescribed by the Department,
with all applicable orders or regulations of other U.S. agencies and
courts, and with all applicable laws of the United States.

This authority shall not be effective during any period when the holder
is not in compliance with the conditions imposed above.  Moreover, this
authority cannot be sold or otherwise transferred without explicit
Department approval under Title 49 of the U.S. Code.

 05/2004

 On May 23, 2006, the applicant filed an additional application.
Although the application was styled in the form of a renewal request, we
are treating it as a supplement to the May 25, 2005 renewal application,
to the extent that it provides updated information as to some aspects of
the original renewal request.


[Federal Register Volume 82, Number 224 (Wednesday, November 22, 2017)]
[Notices]
[Pages 55614-55615]
[FR Doc No: 2017-25295]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-6330]

Bone, Reproductive and Urologic Drugs Advisory Committee; Notice
of Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) announces a
forthcoming public advisory committee meeting of the Bone, Reproductive
and Urologic Drugs Advisory Committee. The general function of the
committee is to provide advice and recommendations to the Agency on
FDA's regulatory issues. The meeting will be open to the public. FDA is
establishing a docket for public comment on this document.

DATES: The public meeting will be held on January 9, 2018, from 8 a.m.
to 5 p.m.

ADDRESSES: College Park Marriott Hotel and Conference Center,
Chesapeake Ballroom, 3501 University Blvd. East, Hyattsville, MD 20783.
The conference center's telephone number is<PHONE_NUMBER>. Answers to
commonly asked questions about FDA Advisory Committee meetings may be
accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2017-N-6330. The docket will close on January
8, 2018. Submit either electronic or written comments on this public
meeting by January 8, 2018. Please note that late, untimely filed
comments will not be considered. Electronic comments must be submitted
on or before January 8, 2018. The https://www.regulations.gov
electronic filing system will accept comments until midnight Eastern
Time at the end of January 8, 2018. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.
    Comments received on or before December 22, 2017, will be provided
to the committee. Comments received after that date will be taken into
consideration by the Agency.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.

     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2017-N-6330 for ``Bone, Reproductive and Urologic Drugs Advisory
Committee; Notice of Meeting; Establishment of a Public Docket; Request
for Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Kalyani Bhatt, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, Fax:<PHONE_NUMBER>, email: [email protected], or FDA Advisory
Committee Information Line, 1-800-741-8138<PHONE_NUMBER> in the
Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down
to the appropriate advisory committee meeting link, or call the
advisory committee information line to learn about possible
modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The committee will discuss new drug application (NDA)
206089, oral testosterone undecanoate capsules, submitted by Clarus
Therapeutics, for the proposed indication of testosterone replacement
in males for conditions associated with a deficiency or absence of
endogenous testosterone: Primary hypogonadism (congenital or acquired)
and hypogonadotropic hypogonadism (congenital or acquired).
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see the
ADDRESSES section) on or before December 22, 2017, will be provided to
the committee. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before December 14, 2017. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by December 15, 2017.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    For press inquiries, please contact the Office of Media Affairs at
[email protected] or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Kalyani Bhatt at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: November 17, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-25295 Filed 11-21-17; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register: June 25, 2008 (Volume 73, Number 123)]
[Notices]
[Page 36090]
[DOCID:fr25jn08-88]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0207] (formerly Docket No. 2007D-0202)

Guidance for Industry: Microbiological Considerations for
Antimicrobial Food Additive Submissions; Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry entitled ``Guidance for
Industry: Microbiological Considerations for Antimicrobial Food
Additive Submissions.'' The guidance explains FDA's current thinking on
a number of microbiological issues unique to the preparation of
premarket submissions for antimicrobial food additives.

DATES:  Submit written or electronic comments on agency guidances at
any time.

ADDRESSES:  Submit written requests for single copies of the guidance
to the Office of Food Additive Safety (HFS-200), Center for Food Safety
and Applied Nutrition, 5100 Paint Branch Pkwy., College Park, MD 20740.
Send two self-addressed adhesive labels to assist that office in
processing your request, or fax your request to<PHONE_NUMBER>. Submit
written comments to the Division of Dockets Management (HFA-305), Food
and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD
20852. Submit electronic comments to http://www.regulations.gov. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
guidance document.

FOR FURTHER INFORMATION CONTACT:  Judith Kidwell, Center for Food
Safety and Applied Nutrition (HFS-265), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of September 25, 2007 (72 FR 54446), FDA
announced the availability of a draft guidance entitled ``Guidance for
Industry: Microbiological Considerations for Antimicrobial Food
Additive Submissions.'' FDA gave interested parties an opportunity to
submit comments on the draft guidance by November 26, 2007. The agency
considered the one received comment as it finalized the guidance. The
guidance announced in this notice finalizes the draft guidance dated
September 2007.
    FDA is issuing this guidance document as level 1 guidance
consistent with FDA's good guidance practices regulation (21 CFR
10.115). The guidance document represents FDA's current thinking on a
number of microbiological issues unique to the preparation of premarket
submissions for antimicrobial food additives. It does not create or
confer any rights for or on any person and does not operate to bind FDA
or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collection of information in 21 CFR 70.25, 71.1, 170.35, and 171.1 have
been approved under OMB control number 0910-0016; the collection of
information in 21 CFR 170.39 has been approved under OMB control number
0910-0298; and the collection of information in 21 CFR 170.101 and
170.106 have been approved under OMB control number 0910-0495.

III. Comments

    Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. The guidance document and received
comments may be seen in the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
    Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA
through FDMS only.

IV. Electronic Access

    Persons with access to the Internet may obtain the guidance at
http://www.cfsan.fda.gov/guidance.html.

    Dated: June 19, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-14397 Filed 6-24-08; 8:45 am]

BILLING CODE 4160-01-S


[Federal Register: May 10, 2010 (Volume 75, Number 89)]
[Notices]
[Page 25917-25919]
[DOCID:fr10my10-107]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket ID FMCSA-2010-0082]

Qualification of Drivers; Exemption Applications; Vision

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of applications for exemptions; request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 22 individuals
for exemption from the vision requirement in the Federal Motor Carrier
Safety Regulations. If granted, the exemptions would enable these
individuals to qualify as drivers of commercial motor vehicles (CMVs)
in interstate commerce without meeting the Federal vision standard.

DATES: Comments must be received on or before June 9, 2010.

ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket ID FMCSA-2010-0082 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://
www.regulations.gov. Follow the on-line instructions for submitting
comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue, SE., West Building Ground
Floor, Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
     Fax: 1-202-493-2251.
    Each submission must include the Agency name and the docket ID for
this Notice. Note: that DOT posts all comments received without change
to http://www.regulations.gov, including any personal information
included in a comment. Please see the Privacy Act heading below.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue, SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The FDMS is available 24 hours each day, 365
days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments on-line.
    Privacy Act: Anyone may search the electronic form of all comments
received into any of our dockets by the name of the individual
submitting the comment (or of the person signing the comment, if
submitted on behalf of an association, business, labor union, etc.).
You may review the DOT's complete Privacy Act Statement in the Federal
Register published on April 11, 2000 (65 FR 19476). This information is
also available at http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Dr. Mary D. Gunnels, Director, Medical
Programs,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA, Department of
Transportation, 1200 New Jersey Avenue, SE., Room W64-224, Washington,
DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m., Monday
through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
for a 2-year period if it finds ``such exemption would likely achieve a
level of safety that is equivalent to, or greater than, the level that
would be achieved absent such exemption.'' FMCSA can renew exemptions
at the end of each 2-year period. The 22 individuals listed in this
notice have each requested an exemption from the vision requirement in
49 CFR 391.41(b)(10), which applies to drivers of CMVs in interstate
commerce. Accordingly, the Agency will evaluate the qualifications of
each applicant to determine whether granting an exemption will achieve
the required level of safety mandated by statute.

Qualifications of Applicants

Clarke C. Boynton

    Mr. Boynton, age 35, has had amblyopia in his left eye since
childhood. The best corrected visual acuity in his right eye is 20/20
and in his left eye, 20/70. Following an examination in 2009, his
ophthalmologist noted, ``In my medical opinion, Mr. Clarke Boynton has
sufficient vision to perform the driving tasks required to operate a
commercial vehicle.'' Mr. Boynton reported that he has driven straight
trucks for 14 years, accumulating 350,000 miles. He holds a Class B
Commercial Driver's License (CDL) from Massachusetts. His driving
record for the last 3 years shows no crashes and no convictions for
moving violations in a CMV.

Clare H. Buxton

    Mr. Buxton, 63, has had a prosthetic left eye since 1998. The best
corrected visual acuity in his right eye is 20/25. Following an
examination in 2009, his optometrist noted, ``Clare has monocular
vision right eye only, but in my opinion, can operate a commercial
motor vehicle safely.'' Mr. Buxton reported that he has driven tractor-
trailer combinations for 40 years, accumulating 5.2 million miles. He
holds a Class A CDL from Michigan. His driving record for the last 3
years shows one crash, for which he was not cited, and no convictions
for moving violations in a CMV.

Raul Charo

    Mr. Charo, 50, has had open angle glaucoma in his right eye since
2006. The best corrected visual acuity in his right eye is 20/60 and in
his left eye, 20/20. Following an examination in 2009, his
ophthalmologist noted, ``In my professional opinion, Mr. Charo has
sufficient vision to perform the driving tasks required to operate a
commercial vehicle.'' Mr. Charo reported that he has driven straight
trucks for 22 years, accumulating 33,000 miles. He holds a Class A CDL
from Illinois. His driving record for the last 3 years shows no crashes
and no convictions for moving violations in a CMV.

Lester M. Ellingson, Jr.

    Mr. Ellingson, 66, has had choroidal melanoma in his left eye since
2000. The best corrected visual acuity in his right eye is 20/20 and in
his left eye, 20/400. Following an examination in 2009, his optometrist
noted, ``In my opinion, Lester has sufficient vision to operate a
commercial vehicle.'' Mr. Ellingson reported that he has driven
straight trucks for 47 years, accumulating 235,000 miles, tractor-
trailer combinations for 40 years, accumulating 960,000 miles and buses
for 40 years, accumulating 20,000 miles. He holds a Class A CDL from
North Dakota. His driving record for the last 3 years shows one crash
and one conviction. His driving record for the last 3 years shows no
crashes and one conviction for a moving violation, speeding in a CMV.
He exceeded the speed limit by 10 mph.

Miguel H. Espinoza

    Mr. Espinoza, 34, has had amblyopia in his left eye since 1989. The
best corrected visual acuity in his right eye is 20/20 and in his left
eye, 20/150. Following an examination in 2009, his optometrist noted,
``He has more than

sufficient vision to perform his driving tasks required to operate a
commercial vehicle.'' Mr. Espinoza reported that he has driven straight
trucks for 10 years, accumulating 140,000 miles. He holds a Class C
operator's license from California. His driving record for the last 3
years shows no crashes and no convictions for moving violations in a
CMV.

Billy R. Gibbs

    Mr. Gibbs, 52, has had amblyopia in his right eye since childhood.
The best corrected visual acuity in his right eye is 20/60 and in his
left eye, 20/20. Following an examination in 2010, his ophthalmologist
noted, ``In my medical opinion, Mr. Gibbs has sufficient vision to
perform the driving tasks required to operate a commercial vehicle.''
Mr. Gibbs reported that he has driven straight trucks for 5 years,
accumulating 60,000 miles and tractor-trailer combinations for 20
years, accumulating 700,000. He holds a Class A CDL from Maryland. His
driving record for the last 3 years shows no crashes and no convictions
for moving violations in a CMV.

Clyde J. Harms

    Mr. Harms, 59, has had amblyopia in his right eye since childhood.
The best corrected visual acuity in his right eye is 20/80 and in his
left eye, 20/20. Following an examination in 2009, his optometrist
noted, ``It is my professional opinion that he is very capable of
performing the driving tasks required to operate a commercial
vehicle.'' Mr. Harms reported that he has driven straight trucks for 33
years, accumulating 148,500 miles. He holds a Class B CDL from
Illinois. His driving record for the last 3 years shows no crashes and
no convictions for moving violations in a CMV.

Ricky P. Hastings

    Mr. Hastings, 55, has had a prosthetic left eye since 1991. The
best corrected visual acuity in his right eye is 20/20. Following an
examination in 2009, his ophthalmologist noted, ``Based on my
examination findings, I determine that Mr. Hastings has sufficient
vision, in this right eye, to perform the driving tasks required to
operate a commercial vehicle.'' Mr. Hastings reported that he has
driven straight trucks for 5 years, accumulating 250,000 miles and
tractor-trailer combinations for 10 years, accumulating 650,000 miles.
He holds a Class A CDL from Texas. His driving record for the last 3
years shows no crashes and no convictions for moving violations in a
CMV.

Wesley V. Holland

    Mr. Holland, 48, has had amblyopia in his left eye since childhood.
The best corrected visual acuity in his right eye is 20/15 and in his
left eye, 20/400. Following an examination in 2010, his optometrist
noted, ``In my medical opinion, Mr. Holland has sufficient vision to
perform the driving tasks required to operate a commercial vehicle.''
Mr. Holland reported that he has driven straight trucks for 16 years,
accumulating 736,000 miles. He holds a Class A CDL from North Carolina.
His driving record for the last 3 years shows no crashes and no
convictions for moving violations in a CMV.

William D. Holt

    Mr. Holt, 48, has had complete loss of vision in his right eye
since childhood. The best corrected visual acuity in his left eye is
20/20. Following an examination in 2009 his optometrist noted, ``I
certify that Mr. Holt does have sufficient vision to drive a commercial
vehicle based on guidelines presented to me prior to the examination.''
Mr. Holt reported that he has driven straight trucks for 30 years,
accumulating 630,000 miles and tractor-trailer combinations for 30
years, accumulating 630,000 miles. He holds a Class A CDL from Arizona.
His driving record for the last 3 years shows no crashes and no
convictions for moving violations in a CMV.

Azizi A. Jamal

    Mr. Jamal, 48, has had amblyopia and glaucoma in his left eye since
childhood. The best corrected visual acuity in his right eye is 20/20
and in his left eye, hand-motion vision. Following an examination in
2010 his ophthalmologist noted, ``I do feel, in my medical opinion,
that he has sufficient vision to perform driving tasks required to
operate a commercial vehicle.'' Mr. Jamal reported that he has driven
straight trucks for 3 years, accumulating 91,800 miles. He holds a
Class D operator's license from New Jersey. His driving record for the
last 3 years shows no crashes and no convictions for moving violations
in a CMV.

William L. Martin

    Mr. Martin, 33, has extensive corioretinal scarring in his right
eye due to a traumatic injury sustained at age 16. The best corrected
visual acuity in his right eye is 20/400 and in his left eye, 20/20.
Following an examination in 2009, his ophthalmologist noted, ``In my
medical opinion William Martin has sufficient vision to perform the
driving tasks required to operate a commercial vehicle.'' Mr. Martin
reported that he has driven straight trucks for 12 years, accumulating
270,000 miles and tractor-trailer combinations for 12 years,
accumulating 270,000 miles. He holds a Class A CDL from Oregon. His
driving record for the last 3 years shows no crashes and no convictions
for moving violations in a CMV.

Gary G. McKown

    Mr. McKown, 60, has had a prosthetic right eye since 1961. The best
corrected visual acuity in his left eye is 20/20. Following an
examination in 2010, his optometrist noted, ``In my opinion, Mr. McKown
has sufficient vision to perform the driving tasks required to operate
a commercial vehicle.'' Mr. McKown reported that he has driven straight
trucks for 2 years, accumulating 10,000 miles and tractor-trailer
combinations for 39 years, accumulating 1.9 million miles. He holds a
Class A CDL from West Virginia. His driving record for the last 3 years
shows no crashes and one conviction for speeding in a CMV. He exceeded
the speed limit by 5 mph.

Larry D. Moss

    Mr. Moss, 55, has had complete loss of vision in his right eye
since 1962 due to a traumatic injury. The best corrected visual acuity
in his left eye is 20/15. Following an examination in 2009 his
optometrist noted, ``It is my medical opinion that Mr. Larry Moss has
sufficient vision to perform the driving tasks required to operate a
commercial vehicle.'' Mr. Moss reported that he has driven straight
trucks for 8 years, accumulating 768,000 miles. He holds a Class C
operator's license from California. His driving record for the last 3
years shows no crashes and no convictions for moving violations in a
CMV.

Leland B. Moss

    Mr. Moss, 47, has had amblyopia in his right eye since childhood.
The best corrected visual acuity in his right eye is 20/200 and in his
left eye, 20/20. Following an examination in 2009 his optometrist
noted, ``I believe his vision is sufficient to perform the driving
tasks required to operate a commercial vehicle.'' Mr. Moss reported
that he has driven straight trucks for 10 years, accumulating 200,000
miles. He holds a Class D operator's license from Vermont. His driving
record for the last 3 years shows no crashes and no convictions for
moving violations in a CMV.

Michael J. Rankin

    Mr. Rankin, 54, has had loss of vision in his right eye since 1989
due to

presumed ocular histoplasmosis. The best corrected visual acuity in his
right eye is 20/300 and in his left eye, 20/20. Following an
examination in 2009, his optometrist noted, ``It is my opinion that he
has sufficient vision to safely operate a commercial vehicle across
interstate borders.'' Mr. Rankin reported that he has driven straight
trucks for 4 years, accumulating 60,000 miles, and tractor-trailer
combinations for 3 years, accumulating 37,500 miles. He holds a Class A
CDL from Ohio. His driving record for the last 3 years shows no crashes
and no convictions for moving violations in a CMV.

Jacob H. Riggle

    Mr. Riggle, 48, has had macular scarring in his right eye since
1999. The best corrected visual acuity in his right eye is 20/400 and
in his left eye, 20/20. Following an examination in 2009, his
optometrist noted, ``In my opinion, Mr. Riggle shows to have sufficient
vision to perform the driving tasks required for a commercial driver
license.'' Mr. Riggle reported that he has driven straight trucks for
28 years, accumulating 2.3 million miles, and tractor-trailer
combinations for 28 years, accumulating 2.5 million miles. He holds a
Class A CDL from Oklahoma. His driving record for the last 3 years
shows no crashes and no convictions for moving violations in a CMV.

Terry L. Rubendall

    Mr. Rubendall, 54, has had complete loss of vision in his left eye
since childhood due to a congenital left orbital tumor. The best
corrected visual acuity in his right eye is 20/15. Following an
examination in 2009, his optometrist noted, ``It is my professional
opinion that Terry has sufficient vision to perform the driving tasks
required to operate a commercial vehicle.'' Mr. Rubendall reported that
he has driven straight trucks for 29 years, accumulating 1.4 million
miles, tractor-trailer combinations for 15 years, accumulating 75,000
miles, and buses for 5 years, accumulating 5,000 miles. He holds a
Class A CDL from Pennsylvania. His driving record for the last 3 years
shows no crashes and no convictions for moving violations in a CMV.

Michael L. Skeens

    Mr. Skeens, 39, has had a prosthetic left eye since childhood. The
best corrected visual acuity in his right eye is 20/20. Following an
examination in 2010, his ophthalmologist noted, ``I, Dr. Jeffrey
Bunning, certify in my medical opinion that Mr. Skeens has sufficient
vision to perform all driving tasks required to operate a commercial
vehicle.'' Mr. Skeens reported that he has driven straight trucks for
13 years, accumulating 416,000 miles, and tractor-trailer combinations
for 3\1/2\; years, accumulating 35,000 miles. He holds a Class A CDL
from Virginia. His driving record for the last 3 years shows no crashes
and no convictions for moving violations in a CMV.

Lee F. Taylor

    Mr. Taylor, 54, has had amblyopia in his left eye since birth. The
best corrected visual acuity in his right eye is 20/20 and in his left
eye, 20/70. Following an examination in 2009, his ophthalmologist
noted, ``In my medical opinion, Lee Taylor has sufficient vision to
perform the required tasks to operate a commercial vehicle.'' Mr.
Taylor reported that he has driven straight trucks for 19 years,
accumulating 855,000 miles, and tractor-trailer combinations for 19
years, accumulating 1 million miles. He holds a Class A CDL from New
Jersey. His driving record for the last 3 years shows no crashes and
one conviction for a moving violation in a CMV. He failed to obey a
traffic control device.

Aaron E. Wright

    Mr. Wright, 42, has had amblyopia and optic nerve damage in his
right eye since 1994. The best corrected visual acuity in his right eye
is 20/400 and in his left eye, 20/20. Following an examination in 2010,
his optometrist noted, ``Mr. Wright has sufficient vision to perform
the driving tasks required to operate a commercial vehicle.'' Mr.
Wright reported that he has driven straight trucks for 2 years,
accumulating 16,000 miles, and tractor-trailer combinations for 3
years, accumulating 315,000 miles. He holds a Class A CDL from
Michigan. His driving record for the last 3 years shows no crashes and
no convictions for moving violations in a CMV.

Michael A. Zingarella, Sr.

    Mr. Zingarella, 39, has had amblyopia and strabismus in his left
eye since childhood. The best corrected visual acuity in his right eye
is 20/20 and in his left eye, count-finger vision. Following an
examination in 2010, his optometrist noted, ``It is my medical opinion
that Mr. Zingarella has more than sufficient vision to perform the
tasks required to operate a commercial vehicle.'' Mr. Zingarella
reported that he has driven straight trucks for 13 years, accumulating
650,000 miles. He holds a Class D operator's license from Connecticut.
His driving record for the last 3 years shows no crashes and one
conviction for a moving violation in a CMV. He failed to use the proper
signal while changing lanes.

Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. The Agency will consider all comments
received before the close of business June 9, 2010. Comments will be
available for examination in the docket at the location listed under
the ADDRESSES section of this notice. The Agency will file comments
received after the comment closing date in the public docket, and will
consider them to the extent practicable.
    In addition to late comments, FMCSA will also continue to file, in
the public docket, relevant information that becomes available after
the comment closing date. Interested persons should monitor the public
docket for new material.

    Issued on: April 23, 2010.
Larry W. Minor,
Associate Administrator for Policy and Program Development.
[FR Doc. 2010-10941 Filed 5-7-10; 8:45 am]
BILLING CODE 4910-EX-P


[Federal Register Volume 86, Number 31 (Thursday, February 18, 2021)]
[Notices]
[Page 10113]
[FR Doc No: 2021-03288]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4483-DR; Docket ID FEMA-2021-0001]

Iowa; Amendment No. 2 to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster declaration
for the State of Iowa (FEMA-4483-DR), dated March 23, 2020, and related
determinations.

DATES: This change occurred on January 10, 2021.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and
Recovery, Federal Emergency Management Agency, 500 C Street SW,
Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency
(FEMA) hereby gives notice that pursuant to the authority vested in the
Administrator, under Executive Order 12148, as amended, Kathy Fields,
of FEMA is appointed to act as the Federal Coordinating Officer for
this disaster.
    This action terminates the appointment of Paul Taylor as Federal
Coordinating Officer for this disaster.

    The following Catalog of Federal Domestic Assistance Numbers
(CFDA) are to be used for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis
Counseling; 97.033, Disaster Legal Services; 97.034, Disaster
Unemployment Assistance (DUA); 97.046, Fire Management Assistance
Grant; 97.048, Disaster Housing Assistance to Individuals and
Households In Presidentially Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance--Disaster Housing
Operations for Individuals and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals and Households--Other
Needs; 97.036, Disaster Grants--Public Assistance (Presidentially
Declared Disasters); 97.039, Hazard Mitigation Grant.

Pete Gaynor,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2021-03288 Filed 2-17-21; 8:45 am]
BILLING CODE 9111-23-P